NCT06831838
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
Recruiting
NAAges 18+InterventionalSupportive careMayo ClinicInvestigator-initiated
~116 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Cognitive Behavioral Therapy based Pain Management Program
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence to Aromatase Inhibitors (AIs)
Measured over Baseline, 3 months, 6 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Barbara Bruce, Ph.D., LP · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
At least 18 years old
ECOG ≤ 2
Stage 0-III HR+ breast cancer in need of strategies to reduce symptoms and improve quality of life
What this trial measures
- Adherence to Aromatase Inhibitors (AIs)Baseline, 3 months, 6 months
Adherence to Aromatase Inhibitors (AIs) medications will be collected as a self-reported question asking the patients if they have taken their medications as prescribed during the past month (yes vs. no).
- AIMSS Follow-up QuestionnaireBaseline, 3 months, 6 months
Subjects will complete the study follow-up questionnaire with study staff to indicate whether they are adhering to medications and to report symptoms.